Drs Donington and Stiles discuss the implications of perioperative immunotherapy trials on early-stage lung cancer management, including the read out of overall survival data from the KEYNOTE-671 trial, definitions of resectability, and the incorporation of new multidisciplinary management guidance.
Drs Donington and Stiles discuss how the findings from the ADAURA trial with adjuvant osimertinib have changed thoracic surgery expectations, the potential surgical implications of the ALINA trial with adjuvant alectinib, and the importance of early-stage molecular testing in lung cancer.
/PRNewswire/ Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today.